Mitochondrial Transplantation Platform
Age-related diseases (e.g., immune senescence, retinal disease, neurodegeneration)
Pre-clinicalActive
Key Facts
Indication
Age-related diseases (e.g., immune senescence, retinal disease, neurodegeneration)
Phase
Pre-clinical
Status
Active
Company
About Mitrix bio
Mitrix Bio is a private, pre-clinical stage biotech founded in 2019 and based in San Francisco, focused on developing mitochondrial transplantation as a new therapeutic modality. The company's platform centers on the industrial-scale production of 'Mitlets'—vesicle-encased, young mitochondria—designed to supplement aged or dysfunctional cells in organs like the brain, retina, and immune system. While still in the research and development phase, Mitrix aims to address a broad spectrum of age-related diseases by targeting the root cause of cellular energy decline. The company is backed by investors including R42 Capital and LongevityTech Fund.
View full company profile